Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Geovax Labs (NQ: GOVX )

0.6090 -0.0210 (-3.33%)
Streaming Delayed Price Updated: 3:59 PM EDT, Jun 8, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 586,233
Open 0.6400
Bid (Size) 0.6020 (1)
Ask (Size) 0.6100 (3)
Prev. Close 0.6300
Today's Range 0.5952 - 0.6534
52wk Range 0.5310 - 4.300
Shares Outstanding 26,443,649
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
GeoVax Partners With ABL to Advance cGMP Production of Vaccine Candidates
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
GeoVax to Participate in Upcoming Industry Meetings
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire

Performance

YTD
-3.07%
-3.07%
1 Month
-8.56%
-8.56%
3 Month
-17.59%
-17.59%
6 Month
-19.37%
-19.37%
1 Year
-67.78%
-67.78%

More News

Read More
GeoVax's Next-Gen Single Dose COVID-19 Vaccine Shows Promising Results
Via Benzinga
GeoVaxs Next-Generation COVID-19 Vaccine Shows High Immunogenicity in Immunocompromised Patients
Via NewMediaWire
Exposures COVID-19
GeoVax Next-Generation COVID-19 Vaccine Data to be Presented at Two Upcoming Scientific Meetings
Via NewMediaWire
Exposures COVID-19
Geovax Labs: Q1 Earnings Insights
Via Benzinga
Geovax Labs's Earnings Outlook
Via Benzinga
Geovax Labs's Earnings: A Preview
Via Benzinga
GeoVax Labs to Participate in A.G.P.'s Virtual Healthcare Conference
Via NewMediaWire
GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update
Via NewMediaWire
Exposures COVID-19
GeoVax to Participate in the 4th Symposium on Infectious Diseases in the Immunocompromised Host
Via NewMediaWire
Exposures COVID-19
Wrap Technologies And 2 Other Stocks Under $2 Insiders Are Aggressively Buying
Via Benzinga
GeoVax to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4, 2023
Via NewMediaWire
GeoVax Labs And 2 Other Penny Stocks Insiders Are Aggressively Buying
Via Benzinga
GeoVax Announces Expansion of Next-Generation COVID-19 Vaccine Rights to Include Omicron Variants and Use Against Orthopoxviruses
Via NewMediaWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate
Via NewMediaWire
Exposures COVID-19
GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine Congress
Via NewMediaWire
GeoVax to Participate at the World Vaccine Congress with Multiple Presentations
Via NewMediaWire
GeoVax Reports 2022 Year-End Financial Results and Provides Corporate Update
Via NewMediaWire
Earnings Scheduled For March 23, 2023
Via Benzinga
Coya Therapeutics Enters First-Of-Its-Kind Partnership With Multi-Billion Dollar Drug Company — Why This Is A Major Moment For Drug Development
Via Benzinga
GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress
Via NewMediaWire
Exposures COVID-19
GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update
Via NewMediaWire
GeoVax to Participate at the 35th Annual Roth Conference
Via NewMediaWire
Benzinga's Top Ratings Upgrades, Downgrades For March 3, 2023
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.